 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
The REVEAL —Risk Evaluation and Education for Alzheimer's Disease— Study is a multi-center, National Human Genome Research Institute (NHGRI) and National Institute on Aging (NIA) funded research project based at Boston University School of Medicine. The goal of REVEAL is to provide healthy adults with genetic susceptibility testing and information about their chances to develop Alzheimer's disease. Eligible participants will be asked to conduct a phone interview during which questions about attitudes toward AD will be asked. Participants will be given the opportunity to meet with a genetic counselor to discuss any family history of AD and learn about the gene associated with AD. Participants will then have the opportunity to have their blood drawn for gene testing and receive an AD risk assessment. Information from the REVEAL Study will be used to determine if it is beneficial to educate people about their potential genetic risk for AD. Who is eligible to participate?Men and women who are between the ages of 18 and 84 years old are eligible to participate. What happens at the visits?Participants in the REVEAL Study are asked to complete three or four study appointments over the course of seven to nine months. These appointments usually take around 30 to 90 minutes to complete and generally consist of speaking with the genetic counselor and filling out written surveys. At one appointment, a brief memory screen will be conducted and a sample of blood will be drawn. There are no physical exams or medical treatments offered as part of this study. Where is the study taking place?Locally, all REVEAL Study appointments are held at the Boston University School of Medicine. Additional study sites include: Case Western Reserve University School of Medicine (Cleveland, OH); Howard University (Washington, DC); and University of Michigan (Ann Arbor, MI). How can I find out more?For more information, please contact the REVEAL Study project manager: Susan Hiraki, M.S. Tel: (617) 638-5355 Key PersonnelRobert C. Green, M.D., M.P.H., Principal Investigator, Project Director Study PublicationsThisted Horsdal H, Vingård Olesen A, Gasse Dr.rer.medic C, Toft Sørensen H, Green RC, Paaske Johnsen S. (2008) Use of Statins and Risk of Hospitalization With Dementia: A Danish Population-Based Case-Control Study. Alzheimer Disease and Associated Disorders (In press). [PDF] Chung WW, Chen CA, Cupples LA, Roberts JS, Hiraki SC, Nair AK, Green RC, Stern RA. (2008) A New Scale Measuring Psychological Impact of Genetic Susceptibility Testing for Alzheimer's disease. Alzheimer Disease and Associated Disorders, (In press). [PDF] Christensen KD, Roberts JS, Royal CDM, Fasaye G, Obisesan T, Cupples LA, Whitehouse PJ, Butson MB, Linnenbringer E, Relkin NR, Farrer L, Cook-Deegan R, Green RC. (2008) Incorporating Ethnicity into Genetic Risk Assessment for Alzheimer's disease: the REVEAL Study Experience. Genetics in Medicine, 10(3). [PDF] Chao, S., Robert, J.S., Marteau, T.M., Silliman, R., Cupples, L.A., Green, RC. (2008) Health Behavior Changes after Genetic Risk Assessment for Alzheimer's Disease: The REVEAL Study. Alzheimer Disease and Associated Disorders, 22(1): 94-97. [PDF] Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P. (2007) The Neuronal Sortilin-related Receptor SORL1 is Genetically associated with Alzheimer disease. Nature Genetics Feb;39(2):168-77. [PDF] LaRusse Eckert S, Katzen H, Roberts J.S., Barber M, Ravdin L.D., Gooding HC, Linnenbringer E, Burack J, Roberts JS, Green RC, Biesecker BB. (2006) Desire for Genetic Susceptibility testing for Alzheimer disease: Perceived Threat and the Need for Information and Control in the REVEAL Study. Patient Education & Counseling 64:259-267. [PDF] Binetti G, Benussi L, Roberts S, Villa A, Pasqualetti P, Sheu C-F, Gigola L, Lussignoli G, Dal Forno G, Barbiero L, Corbellini, Green RC, Rossini PM, Ghidoni R. (2006) Areas of Intervention for Genetic Counselling of Dementia: Cross-cultural comparison between Italians and Americans. Patient Education & Counseling, Dec;64(1-3):285-93. [PDF] Lock M, Freeman J, Sharples R, Lloyd S. (2006) When it Runs in the Family: Situating Knowledge about Susceptibility Genes. Public Understanding of Science , 15(3):277-300. [PDF] Erlich PM, Lunetta KL, Cupples LA, Huyck M, Green RC, Baldwin CT, Farrer LA. (2006) Polymorphisms in the PON Gene Cluster are associated with Alzheimer disease. Human Molecular Genetics, 15:77-85. [PDF] Eckert SL, Katzen H, Roberts JS, Barber M, Ravdin LD, Relkin NR, Whitehouse PJ, Green RC. (2006) Recall of disclosed Apolipoprotein E Genotype and Lifetime Risk Estimate for Alzheimer’s disease: The REVEAL Study. Genetics in Medicine, 8:746-751. [PDF] Tsai DH, Green RC, Benke KS, Silliman RA, Farrer LA (2006) Predictors of Subjective Memory Complaint in Cognitively Normal Relatives of Patients with Alzheimer’s disease. Journal of Neuropsychiatry and Clinical Neuroscience, 18:384-388. [PDF] Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S. (2006) Diabetes Mellitus and Risk of Developing Alzheimer disease. Archives of Neurology, 63:1551-1555. [PDF] Akomolafe A, Lunetta KL, Erlich PM, Cupples LA, Baldwin CT, Huyck M, Green RC, Farrer LA. (2006) Genetic Association between Endothelial Nitric Oxide Synthase (NOS3) and Alzheimer disease. Clinical Genetics, 70:49-56. [PDF] Yip G, McKee A, Green RC, Wells J, Young H, Cupples LA, Farrer LA: APOE, Vascular Pathology and the AD Brain. Neurology, 65:259-265, 2005. [PDF] LaRusse S, Roberts JS, Marteau TM, Katzen H, Linnenbringer EL, Barber M, Whitehouse P, Quaid K, Brown T, Green RC, Relkin NR. (2005) Genetic Susceptibility Testing versus Family History-based Risk Assessment: Impact on Perceived Risk of Alzheimer disease. Genetics in Medicine, 7:48-53. [PDF] Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA. (2005) Postmenopausal hormone therapy and Alzheimer’s disease risk: Interaction with age. Journal of Neurology, Neurosurgery and Psychiatry, 76:103-105. [PDF] Roberts JS, Barber M, Brown T, Cupples LA, Farrer L, LaRusse SA, Post S, Quaid K, Ravdin L, Relkin N, Sadovnick D, Whitehouse P, Woodard J, Green RC. (2004) Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multi-site, randomized clinical trial. Genetics in Medicine, 6:197-203. [PDF] Cupples LA, Farrer LA, Sadovnick D, Relkin N, Whitehouse P, Green RC. (2004) Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: The REVEAL Study. Genetics in Medicine, 6:192-196. [PDF] Roberts JS, LaRusse SA, Katzen H, Whitehouse PJ, Barber M, Post SG, Relkin N, Quaid K, Pietrzak RH, Cupples LA, Farrer LA, Brown T, Green RC (2003) Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer’s disease. Alzheimer Disease and Related Disorders, 17:86-93. [PDF] Roberts JS, Connell CM, Cisewski D, Hipps YG, Demissie S, Green RC. (2003) Differences between African Americans and whites in their perceptions of Alzheimer disease. Alzheimer's Disease and Associated Disorders Jan-Mar,17(1):19-26. [PDF] Bachman DL, Green RC, Benke KS, Cupples LA, Farrer LA; MIRAGE Study Group. (2003) Comparison of Alzheimer's disease risk factors in white and African American families. Neurology, Apr 22;60(8):1372-4. [PDF] Hipps YG, Roberts JS, Green RC (2003) Differences between African Americans and whites in their attitudes toward genetic testing for Alzheimer’s disease. Genetic Testing, 7:39-44. [PDF] Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, DeCarli C, Kukull W, Chui H, Edeki T, Griffith P, Friedland RP, Bachman D, Farrer LA. (2003) Depression as a risk factor for Alzheimer disease. Archives of Neurology, 60:753-759. [PDF] Green RC. (2002) Genetic susceptibility testing for Alzheimer’s disease: Has the moment arrived. Alzheimer’s Care Quarterly, 3:208-214. [PDF] Barber M, Whitehouse PJ. (2002) Susceptibility testing for Alzheimer’s disease: race for the future. Lancet Neurology, 1:10. [PDF] Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA, MIRAGE Study Group (2002) Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA, Jan 16;287(3):329-36. [PDF] Graff-Radford N, Green RC, Go R, Edeki T, Bachman D, Griffith P, Williams M, Hipps Y, Haines JL, Cupples LA, Farrer LA: (2002) Association between APOE genotype and Alzheimer disease in African Americans. Archives of Neurology, 59:594-600. [PDF] Demissie S, Green RC, et al.: (2002) Reliability of information collected by proxy in family studies of Alzheimer’s disease. Neuroepidemiology, 20:105-111. [PDF] Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al (1997) Effects of age, gender and ethnicity on the association between Apolipoprotein E genotype and Alzheimer disease. Journal of the American Medical Association, 278:1349-1356. [PDF] Green RC, Clarke VC, Thompson NJ, Woodard JL, Letz R. (1997) Early detection of Alzheimer’s disease: Methods, markers and misgivings. Alzheimer Disease and Associated Disorders, 11:S1-5. [PDF] Farrer LA, Cupples LA, Kukull WA, Volicer L, Wells JM, Kurz A, Green RC, Chui H, et al (1997) Risk of Alzheimer disease is associated with parental age among apolipoprotein E e4 heterozygotes. Alzheimer’s Research, 3:83-91. Rao VS, Cupples LA, van Duijn CM, Kurz A, Green RC, et al: (1996) Evidence for major gene inheritance of Alzheimer disease in families of patients with and without ApoE e4. American Journal of Human Genetics, 59:664-675. [PDF] Farrer LA, Cupples LA, van Duijn CM, Kurz A, Zimmer R, Müller U, Green RC, et al (1995) Apolipoprotein E genotype in patients with Alzheimer’s disease: Implications for the risk of dementia among relatives. Annals of Neurology, 38:797-808. [PDF]
|
|
 |
 |
 |
 |
 |
|